Clesrovimab (1) – Enflonsia®
Secondary prevention of RSV infections in children during their first RSV season
Characteristics
| Start date | 01.06.2026 |
|---|---|
| Resolution | 19.11.2026 – active procedure |
| INN | Clesrovimab |
| Brand name | Enflonsia® |
| Pharm. company | MSD Sharp & Dohme GmbH |
| G-BA Procedure ID | D-1268 |
| Therapeutic area | Infectious diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions